<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Iran Red Crescent Med J</journal-id><journal-id journal-id-type="iso-abbrev">Iran Red Crescent Med J</journal-id><journal-id journal-id-type="publisher-id">Kowsar</journal-id><journal-title-group><journal-title>Iranian Red Crescent Medical Journal</journal-title></journal-title-group><issn pub-type="ppub">2074-1804</issn><issn pub-type="epub">2074-1812</issn><publisher><publisher-name>Kowsar</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22737548</article-id><article-id pub-id-type="pmc">3372025</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>The Effect of Selenium Administration on Restless Leg Syndrome Treatment</article-title><alt-title alt-title-type="short">Selenium in restless leg syndrome</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rahimdel</surname><given-names>A G</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ayatollahi</surname><given-names>P</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zeinali</surname><given-names>A</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mehrabanian</surname><given-names>N</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mellat-Ardekani</surname><given-names>A</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="corresp" rid="COR1">*</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Neurology, Shahid Sadooghi Hospital, Yazd University of Medical Science, Yazd, Iran</aff><author-notes><corresp id="COR1"><label>*</label>Correspondence: Ali Mellat-Ardekani, MD, Assistant Professor of Neurology, Shahid Sadooghi Hospital, Yazd University of Medical Science, Yazd, Iran. Tel.: +98-351-8224001, E-mail: <email>Ali_mellat@ssu.ac.ir</email></corresp></author-notes><pub-date pub-type="ppub"><month>1</month><year>2012</year></pub-date><pub-date pub-type="epub"><day>01</day><month>1</month><year>2012</year></pub-date><volume>14</volume><issue>1</issue><fpage>14</fpage><lpage>19</lpage><history><date date-type="received"><day>22</day><month>5</month><year>2011</year></date><date date-type="accepted"><day>14</day><month>9</month><year>2011</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2012, Kowsar Corp.</copyright-statement><copyright-year>2012</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract abstract-type="executive-summary"><sec id="st1"><title>Background</title><p>Restless leg syndrome (RLS) is defined as an uncomfortable feeling in the limbs which is prominently sensed in legs. Dopamine system involvement is considered as the base of RLS's etiology. Because of safety, anti-oxidant and dopaminergic promoting action of selenium, this study aims to investigate the effect of selenium on restless leg syndrome treatment.</p></sec><sec id="st2"><title>Methods</title><p>Sixty patients with primary RLS were enrolled in this clinical trial (Irct2011103015943n1). It was based on 3 periods of drug prescription with one month wash out period. As placebo, 50 and 200 &#x003bc;g of selenium were administered in each separated month. The diagnosis was based on criteria published by IRLSG (International RLS Study Group). The questionnaire included 10 questions while each question&#x02019;s rating was between 0 and 4. Points between 1 and 10 were considered mild, 11 to 20 as moderate, 21 to 30 as severe and 31 to 40 as very severe. After end of each month of drug consumption, questionnaires were completed and each subject was asked to report the severity of disease and side effects of the drugs. At least 10 declines in scale were considered as appropriate responses.</p></sec><sec id="st3"><title>Results</title><p>Improvement (decline IRLS score &#x0003e;10) was significantly higher in selenium (50 and 200 &#x003bc;g) than placebo group.</p></sec><sec id="st4"><title>Conclusion</title><p>Selenium prescription in daily recommended dose of 50 &#x003bc;g instead of a dopamine agonist would be an alternative treatment in improvement of RLS symptoms.</p></sec></abstract><kwd-group kwd-group-type="author"><kwd>Restless leg syndrome</kwd><kwd>Selenium</kwd><kwd>Treatment</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Restless leg syndrome (RLS) is defined as an uncomfortable feeling in the limbs which is prominently sensed in legs and rarely in arms.[<xref ref-type="bibr" rid="R1">1</xref>]&#x000a0;This disturbing feeling leads to restless and forces patient to move the limbs which is pathognomonic manifestation of RLS.</p><p>This movement leads to complete but temporary relief of symptoms. These symptoms occur only in rest and are intensified in evening or night time.[<xref ref-type="bibr" rid="R1">1</xref>]&#x000a0;The prevalence of disease was shown to be 5-10%.[<xref ref-type="bibr" rid="R1">1</xref>][<xref ref-type="bibr" rid="R2">2</xref>][<xref ref-type="bibr" rid="R3">3</xref>]&#x000a0;and the prevalence increased by aging.[<xref ref-type="bibr" rid="R3">3</xref>]&#x000a0;In addition to sensory symptoms, motor symptoms such as periodic limb movement syndrome, myoclonic Jerking exist during the patient's sleep.[<xref ref-type="bibr" rid="R1">1</xref>][<xref ref-type="bibr" rid="R2">2</xref>]&#x000a0;Since these symptoms may occur during sleep, most of patients have some difficulty in start of sleeping or during sleep which may lead to fatigue and excessive daily sleepiness. Thus RLS is one of the most important causes of insomnia and sleepiness during the day.[<xref ref-type="bibr" rid="R4">4</xref>]&#x000a0;The etiology of RLS is not precisely defined yet but it may be primary (idiopathic) or secondary. Primary cases are commonly genetical and are presented as autosomal dominant patterns.[<xref ref-type="bibr" rid="R5">5</xref>][<xref ref-type="bibr" rid="R6">6</xref>][<xref ref-type="bibr" rid="R7">7</xref>][<xref ref-type="bibr" rid="R8">8</xref>]&#x000a0;Secondary types are associated with diseases such as iron deficiency anemia, folic acid deficiency, renal failure and physiological conditions such as pregnancy.[<xref ref-type="bibr" rid="R1">1</xref>][<xref ref-type="bibr" rid="R9">9</xref>]&#x000a0;Also some case reports showed an association between RLS and diabetes melitus, rhematoid arthritis and amyloidosis.[<xref ref-type="bibr" rid="R1">1</xref>][<xref ref-type="bibr" rid="R9">9</xref>]</p><p>RLS may be induced secondary to drug consumption such as lithium, three cyclic antidepressants, dopamine blockers like metoclopramide and phenothiazines.[<xref ref-type="bibr" rid="R1">1</xref>][<xref ref-type="bibr" rid="R2">2</xref>][<xref ref-type="bibr" rid="R3">3</xref>]&#x000a0;Some facts such as response to dopaminergic drugs, drug induced RLS like anti-dopaminergics, hypoactivity of dopamine system, decreased connection to dopamine receptors in basal ganglia[<xref ref-type="bibr" rid="R4">4</xref>][<xref ref-type="bibr" rid="R10">10</xref>][<xref ref-type="bibr" rid="R11">11</xref>]&#x000a0;implicate this hypothesis that dopamine system involvement may be the main cause. The diagnosis is clinical and the most important role in diagnosis is the history of uncomfortable feeling in limbs which occurs only at rest and is aggravated in evening and night time and is relieved by limb movement.[<xref ref-type="bibr" rid="R1">1</xref>][<xref ref-type="bibr" rid="R11">11</xref>]&#x000a0;Diagnostic criteria published by IRLSG (International RLS Study Group) were shown in <xref ref-type="table" rid="s1tbl1">Table 1</xref>.[<xref ref-type="bibr" rid="R12">12</xref>]&#x000a0;Some laboratory studies are necessary for diagnosis completion including renal function test, cell blood count, serum iron, ferritin and folic acid levels, EMG-NCV and polysomnography for periodic limb movement syndrome(PLMS).[<xref ref-type="bibr" rid="R1">1</xref>][<xref ref-type="bibr" rid="R4">4</xref>][<xref ref-type="bibr" rid="R11">11</xref>]&#x000a0;In recent years, questionnaire for diagnosis and severity determination of RLS has been established by Benoy and Kohnen which is a gold standard for the diagnosis and severity determination. The questionnaire includes 10 questions while each question is rated between 0 and 4. Points between 1 and 10 are considered mild, 11 to 20 as moderate, 21 to 30 as severe and 31 to 40 cas very severe.[<xref ref-type="bibr" rid="R4">4</xref>][<xref ref-type="bibr" rid="R9">9</xref>][<xref ref-type="bibr" rid="R13">13</xref>][<xref ref-type="bibr" rid="R14">14</xref>]&#x000a0;Differential diagnosis are peripheral neuron diseases such as painful peripheral neuropathy, vascular diseases such as peripheral vascular diseases, varicose and erythromelalgia, movement disorders such as akathisia, extra pyramidal tremor, etc.[<xref ref-type="bibr" rid="R1">1</xref>][<xref ref-type="bibr" rid="R4">4</xref>][<xref ref-type="bibr" rid="R11">11</xref>]RLS treatment is based on two approaches including pharmacologic and non-pharmacologic. Nonpharmacologic approaches include treatment of the underlying causes like iron supplementary consumption in iron deficient patients, kidney transplantation in uremic patients, drug induced RLS withdrawal, prevention of stimulating subject consumptions such nicotine, alcohol and caffeine. Also sleep hygiene has an important role in reduction of the disturbances.[<xref ref-type="bibr" rid="R1">1</xref>][<xref ref-type="bibr" rid="R4">4</xref>][<xref ref-type="bibr" rid="R9">9</xref>]Pharmacologic approaches include dopaminergic drugs such as levodopa,[<xref ref-type="bibr" rid="R9">9</xref>][<xref ref-type="bibr" rid="R15">15</xref>]&#x000a0;pramipexole,[<xref ref-type="bibr" rid="R9">9</xref>]&#x000a0;ropinrinol[<xref ref-type="bibr" rid="R2">2</xref>][<xref ref-type="bibr" rid="R9">9</xref>][<xref ref-type="bibr" rid="R15">15</xref>]&#x000a0;and pergolide,[<xref ref-type="bibr" rid="R2">2</xref>][<xref ref-type="bibr" rid="R15">15</xref>]&#x000a0;benzodiazepines,[<xref ref-type="bibr" rid="R15">15</xref>]&#x000a0;opioids such as propoxyphen subsulicylate,[<xref ref-type="bibr" rid="R2">2</xref>]&#x000a0;antiepileptics such as gabapentin,[<xref ref-type="bibr" rid="R2">2</xref>]&#x000a0;iron and folic acid.[<xref ref-type="bibr" rid="R15">15</xref>]</p><table-wrap id="s1tbl1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Diagnostic criteria for RLS</title></caption><table frame="hsides" rules="groups"><thead><tr><td colspan="2" rowspan="1"><bold><italic>Essential criteria</italic></bold></td></tr></thead><tbody><tr><td rowspan="1" colspan="1">1.</td><td rowspan="1" colspan="1">An urge to move the legs usually accompanied by uncomfortable and unpleasant sensation in the legs.</td></tr><tr><td rowspan="1" colspan="1">2.</td><td rowspan="1" colspan="1">The urge to move or unpleasant sensations to be begun or worsen during periods of rest or inactivity such as lying or sitting.</td></tr><tr><td rowspan="1" colspan="1">3.</td><td rowspan="1" colspan="1">The urge to move or unpleasant sensations to be partially or totally relieved by movement such as walking or stretching at least as long as the activity continues.</td></tr><tr><td rowspan="1" colspan="1">4.</td><td rowspan="1" colspan="1">The urge to move or unpleasant sensation to be worsen in the evening or night than during the day or only to be occurred in the evening or night.</td></tr><tr><td colspan="2" rowspan="1">Supportive features</td></tr><tr><td rowspan="1" colspan="1">1.</td><td rowspan="1" colspan="1">Positive family history</td></tr><tr><td rowspan="1" colspan="1">2.</td><td rowspan="1" colspan="1">Positive response to dopaminergic therapy</td></tr><tr><td rowspan="1" colspan="1">3.</td><td rowspan="1" colspan="1">Periodic limbs movements</td></tr><tr><td colspan="2" rowspan="1">Associated features</td></tr><tr><td rowspan="1" colspan="1">1.</td><td rowspan="1" colspan="1">Natural clinical course</td></tr><tr><td rowspan="1" colspan="1">2.</td><td rowspan="1" colspan="1">Sleep disturbance</td></tr><tr><td rowspan="1" colspan="1">3.</td><td rowspan="1" colspan="1">Medical evaluation/physical examination.</td></tr></tbody></table></table-wrap><p>Selenium was discovered by Brezilus in 1814.[<xref ref-type="bibr" rid="R16">16</xref>] In 1957, Foltz and Schwarz implicated that selenium is a rare essential element existing in dietary regimen and has a preventive role for the diseases.[<xref ref-type="bibr" rid="R17">17</xref>] Body selenium concentration is related to its soil concentration.[<xref ref-type="bibr" rid="R18">18</xref>][<xref ref-type="bibr" rid="R19">19</xref>] This concentration in some countries like United States of America is high and is low in China.[<xref ref-type="bibr" rid="R20">20</xref>][<xref ref-type="bibr" rid="R21">21</xref>][<xref ref-type="bibr" rid="R22">22</xref>] In 1973, Rotrack and colleagues demonstrated the anti-oxidative role of selenium.[<xref ref-type="bibr" rid="R15">15</xref>] Role of selenium as anti-oxidant and anti-inflammatory in reverse striatal dopamine depletion[<xref ref-type="bibr" rid="R23">23</xref>] and decrease in thyrosine hydroxylase activity were shown.[<xref ref-type="bibr" rid="R24">24</xref>][<xref ref-type="bibr" rid="R25">25</xref>] Selenium is administered by two routes in selenium deficient patients including enteral and parenteral. Also it is prescribed as supplementary diet in pregnant or breast-feeding mothers.[<xref ref-type="bibr" rid="R26">26</xref>] In advised doses, no side effects were reported. Even no intoxicated cases with doses up to 400 mg for prostate cancer prevention were shown.[<xref ref-type="bibr" rid="R27">27</xref>][<xref ref-type="bibr" rid="R28">28</xref>][<xref ref-type="bibr" rid="R29">29</xref>][<xref ref-type="bibr" rid="R30">30</xref>] Because of its safety, and anti-oxidative and dopaminergic promoting actions and dopaminergic agonist side effects, we were encouraged to establish this study to determine the effect of selenium in RLS treatment.</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and Methods</title><p>In our study, which began in June 2010 and lasted until November 2010, initially 68 patients were enrolled with diagnosis of primary RLS based on IRLSSG. The trial was an experimental study and was registered in IRCT (Code: Irct2011103015943n1). All patients passed the full exams by two neurologists. None of examiners had any knowledge about the colleague's diagnosis. Patients diagnosed as primary RLS by two neurologists were enrolled. The inclusion criteria were (i) Severity of symptoms at least to be moderate (point &#x0003e;10 based on IRLS) and (ii) Patients to be in primary RLS category. All patients underwent routine laboratory exams too. After confirmation, primary cases were enrolled. Eight patients were omitted during the study because of low compliance and insufficient data feedback and finally 60 patients passed the clinical trial successfully. All patients signed an informed consent and were informed for steps of clinical trial and the probable side effect of the drug. The trial was based on 3 periods of drug prescription (every period of the last one month) with one month wash out period. Only the designer of study was aware of the order of drug administration and the others (neurologists, drug administrators and patients) were blind to the pattern and order of drug administration. <xref ref-type="table" rid="s2tbl2">Table 2</xref> shows the steps of trial.</p><table-wrap id="s2tbl2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Steps of trial</title></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1"><bold>State</bold></td><td rowspan="1" colspan="1"><bold>Placebo</bold></td><td rowspan="1" colspan="1"><bold>Washout</bold></td><td rowspan="1" colspan="1"><bold>50 &#x003bc;g selenium</bold></td><td rowspan="1" colspan="1"><bold>Washout</bold></td><td rowspan="1" colspan="1"><bold>200 &#x003bc;g selenium</bold></td></tr></thead><tbody><tr><td rowspan="1" colspan="1">Duration</td><td rowspan="1" colspan="1">One month</td><td rowspan="1" colspan="1">One month</td><td rowspan="1" colspan="1">One month</td><td rowspan="1" colspan="1">One month</td><td rowspan="1" colspan="1">One month</td></tr></tbody></table></table-wrap><p>Placebo, 50 and 200 mg selenium were prescribed as capsules in equal shape and form. Patients and investigators did not know about the materials inside the capsules. The capsules were delivered to patients in three distinctive same packages with information insides, including start and end of the data. During the trial, all patients were questioned regularly about the consumption and dose effects of the medication and were encouraged to use the drugs precisely. After the end of each month of drug consumption, questionnaires were completed and asked them to describe the severity of the disease and any side effects of the drug. At least 10 declines in scale were considered as an appropriate response. All statistical analyses were performed using SPSS software (version 11.5, Chicago, IL, USA).The results were shown as mean&#x000b1;SD. In every period, before-after scores of males and females were analyzed separately by using nonparametric Wilcoxon test. Comparison of the effect of the drug in every period between males and females was assessed by Mann-Whitney test. All before-after scores in the three groups were compared together by Freedman test. P-value of &#x0003c; 0.05 was considered as statistically significant.</p></sec><sec sec-type="results" id="s3"><title>Results</title><p>Sixty patients (34 females, mean age: 54&#x000b1;11.4 and 26 males, mean age: 49&#x000b1;12.3) were enrolled. <xref ref-type="table" rid="s3tbl3">Table 3</xref> shows the rate of placebo and selenium efficacy. Rate of improvement (decline IRLS score&#x0003e;10) was signifi&#x000ad;cantly higher in selenium than placebo group. Im&#x000ad;provement rate between 50 and 200 mg of selenium consumption was not significantly different.</p><table-wrap id="s3tbl3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Score decline comparison between placebo and 50 and 200 &#x000b5;g of selenium.</title></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1"><bold>Score</bold><bold> decline</bold></td><td rowspan="1" colspan="1"><bold>Placebo</bold><bold> No. (%)</bold></td><td rowspan="1" colspan="1"><bold>50 &#x000b5;g selenium </bold><bold>No. (%)</bold></td><td rowspan="1" colspan="1"><bold>200 &#x000b5;g selenium</bold><bold> No. (%)</bold></td></tr></thead><tbody><tr><td rowspan="1" colspan="1">10-15</td><td rowspan="1" colspan="1">11 (18.3)</td><td rowspan="1" colspan="1">27 (45)</td><td rowspan="1" colspan="1">30 (50)</td></tr><tr><td rowspan="1" colspan="1">15-20</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">4 (7)</td><td rowspan="1" colspan="1">6 (10)</td></tr><tr><td rowspan="1" colspan="1">Total</td><td rowspan="1" colspan="1">11 (18.3)</td><td rowspan="1" colspan="1">31 (52)</td><td rowspan="1" colspan="1">36 (60)</td></tr></tbody></table></table-wrap><p>Patients score before and after treatment with pla&#x000ad;cebo, 50 and 200 &#x003bc;g of selenium were shown in <xref ref-type="table" rid="s3tbl4">Table 4</xref>. There were no significant differences between males and females in response to placebo, 50 and 200 &#x003bc;g of selenium&#x000a0;(p&#x000a0;values respectively=0.489, 0.473 and 0.446). Decline in score after treatment by 50 and 200 &#x003bc;g of selenium was significantly higher than pla&#x000ad;cebo group (Both p&#x000a0;values were less than 0.001). Also difference between 50 and 200 &#x003bc;g of selenium was significant&#x000a0;(p&#x000a0;value=0.007).</p><table-wrap id="s3tbl4" orientation="portrait" position="float"><label>Table 4</label><caption><title>Score comparison before and after treatment.</title></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="2" colspan="1"><bold>Score mean(SD)<xref ref-type="table-fn" rid="Fs3tbl4a">a</xref></bold></td><td colspan="3" align="center" rowspan="1"><bold>Placebo</bold></td><td colspan="3" align="center" rowspan="1"><bold>50 &#x000b5;g</bold></td><td colspan="3" align="center" rowspan="1"><bold>200 &#x000b5;g</bold></td></tr><tr><td rowspan="1" colspan="1"><bold>Before</bold></td><td rowspan="1" colspan="1"><bold>After</bold></td><td rowspan="1" colspan="1"><bold><italic>P</italic></bold><bold> value</bold></td><td rowspan="1" colspan="1"><bold>Before</bold></td><td rowspan="1" colspan="1"><bold>After</bold></td><td rowspan="1" colspan="1"><bold><italic>P</italic></bold><bold> value</bold></td><td rowspan="1" colspan="1"><bold>Before</bold></td><td rowspan="1" colspan="1"><bold>After</bold></td><td rowspan="1" colspan="1"><bold><italic>P</italic></bold><bold> value</bold></td></tr></thead><tbody><tr><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">27.73 (6.91)</td><td rowspan="1" colspan="1">21.96 (5.32)</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">26.32 (5.34)</td><td rowspan="1" colspan="1">13.50 (4.24)</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">25.65 (5.09)</td><td rowspan="1" colspan="1">11.63 (4.57)</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">29.21 (6.34)</td><td rowspan="1" colspan="1">22.87 (5.71)</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">27.84 (4.86)</td><td rowspan="1" colspan="1">14.95 (4.52)</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">27.23 (4.91)</td><td rowspan="1" colspan="1">13.19 (3.82)</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td rowspan="1" colspan="1">Total</td><td rowspan="1" colspan="1">28.57 (5.82)</td><td rowspan="1" colspan="1">22.48 (4.32)</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">27.03 (4.67)</td><td rowspan="1" colspan="1">14.17 (4.02)</td><td rowspan="1" colspan="1">&#x0003c;0.001</td><td rowspan="1" colspan="1">25.89 (5.44)</td><td rowspan="1" colspan="1">11.86 (4.62)</td><td rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn id="Fs3tbl4a"><p><sup>a</sup> SD: Standard Deviation</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>In our study, females were more afflicted by primary RLS than males (34 vs. 26).This may be due to sexual hormone effects, dietary regimen, psychologic and sleep problems in this gender. Also silent coincidence disease in females may be more than males which we could not find them precisely.</p><p><xref ref-type="table" rid="s4tbl5">Table 5</xref> shows the comparison between our study and other results, using RLS score for RLS responses to treatment. According to <xref ref-type="table" rid="s4tbl5">Table 5</xref>, in most studies, the rate of score decline by placebo ranged between score of 5-8. The role of placebo was investigated in declining score of RLS.[<xref ref-type="bibr" rid="R32">32</xref>] Increasing the opioid and dopaminergic system of brain may play an important role.[<xref ref-type="bibr" rid="R32">32</xref>] Maximal decrement in score was correlated to dopaminergic agonists (17.2 by trans-dermal roting-tone), but the interesting fact was that despite the more declines in scores by dopminergics, loss of side effects by selenium consumption and safety use of selenium and score decline to 12.86, less compliance and more cost of dopaminergics, selenium may be more and well tolerated. Several studies implicate the role of selenium in reconstruction of the dopaminergic system.[<xref ref-type="bibr" rid="R23">23</xref>][<xref ref-type="bibr" rid="R24">24</xref>][<xref ref-type="bibr" rid="R25">25</xref>] Score declines by 50 and 200 &#x000b5;g of selenium were 12.86 and 14.03 respectively and this difference was statistically significant (p=0.007) but practically this difference was not cost effective. So we preferred to choose 50 &#x000b5;g of selenium for RLS treatment.</p><table-wrap id="s4tbl5" orientation="portrait" position="float"><label>Table 5</label><caption><title>Comparison of IRLS score decline between studies</title></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="2" colspan="1"><bold>Study</bold></td><td rowspan="2" colspan="1"><bold>Country</bold></td><td rowspan="2" colspan="1"><bold>Year</bold></td><td colspan="2" align="center" rowspan="1"><bold>IRLS score decline</bold></td><td rowspan="2" colspan="1"><bold>Price in Iran</bold><bold> (Consumption dose per day)</bold></td></tr><tr><td rowspan="1" colspan="1"><bold>Placebo</bold></td><td rowspan="1" colspan="1"><bold>Drug</bold></td></tr></thead><tbody><tr><td rowspan="1" colspan="1">Rahimdel</td><td rowspan="1" colspan="1">Iran</td><td rowspan="1" colspan="1">2010</td><td rowspan="1" colspan="1">6.09</td><td rowspan="1" colspan="1">12.86 (Selenium)</td><td rowspan="1" colspan="1">0.2 $<xref ref-type="table-fn" rid="Fs4tbl5a">a</xref></td></tr><tr><td rowspan="1" colspan="1">Agarwal et al.[<xref ref-type="bibr" rid="R26">26</xref>]</td><td rowspan="1" colspan="1">USA</td><td rowspan="1" colspan="1">2010</td><td rowspan="1" colspan="1">8.80</td><td rowspan="1" colspan="1">13.20 (Gabapentine)</td><td rowspan="1" colspan="1">1 $<xref ref-type="table-fn" rid="Fs4tbl5a">a</xref></td></tr><tr><td rowspan="1" colspan="1">Hogl et al.[<xref ref-type="bibr" rid="R27">27</xref>]</td><td rowspan="1" colspan="1">Austria</td><td rowspan="1" colspan="1">2010</td><td rowspan="1" colspan="1">_</td><td rowspan="1" colspan="1">17.20 (Transdermal rotigotine)</td><td rowspan="1" colspan="1">N/A<xref ref-type="table-fn" rid="Fs4tbl5b">b</xref></td></tr><tr><td rowspan="1" colspan="1">Walters et al.[<xref ref-type="bibr" rid="R28">28</xref>]</td><td rowspan="1" colspan="1">USA</td><td rowspan="1" colspan="1">2004</td><td rowspan="1" colspan="1">8.70</td><td rowspan="1" colspan="1">11.20 (Ropinirole)</td><td rowspan="1" colspan="1">0.5 $<xref ref-type="table-fn" rid="Fs4tbl5a">a</xref></td></tr><tr><td rowspan="1" colspan="1">Aizuwa et al.[<xref ref-type="bibr" rid="R29">29</xref>]</td><td rowspan="1" colspan="1">Japan</td><td rowspan="1" colspan="1">2005</td><td rowspan="1" colspan="1">_</td><td rowspan="1" colspan="1">14.80 (Cabergoline)</td><td rowspan="1" colspan="1">4 $<xref ref-type="table-fn" rid="Fs4tbl5a">a</xref></td></tr></tbody></table><table-wrap-foot><fn id="Fs4tbl5a"><p><sup>a</sup> $: US dollar</p></fn><fn id="Fs4tbl5b"><p><sup>b</sup> N/A: Not Available</p></fn></table-wrap-foot></table-wrap><p>Selenium in daily recommended dose of 50 &#x000b5;g declines the score of RLS largely which may be due to improvement in the dopaminergic pathway (reverse thyrosine hydroxylase activity and prevention of the striatal dopamine depletion). Finally due to absence of side effects reported form selenium consumption, we can recommend selenium administration next to or instead of dopamine agonist for RLS symptoms improvement.</p></sec></body><back><ack><p>This study was supported by a grant from the Vice Chancellor for Research of Yazd University of Medical Science.</p></ack><fn-group><fn fn-type="conflict"><p><bold>Conflict of interest: </bold>None declared.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wetter</surname><given-names>TC</given-names></name><name><surname>Pollm&#x000e4;cher</surname><given-names>T</given-names></name></person-group><article-title>Restless legs and periodic leg movements in sleep syndromes</article-title><source>J Neurol</source><year>1997</year><volume>244</volume><fpage>S37</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1007/BF03160570</pub-id><pub-id pub-id-type="pmid">9112588</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silber</surname><given-names>MH</given-names></name><name><surname>Ehrenberg</surname><given-names>BL</given-names></name><name><surname>Allen</surname><given-names>RP</given-names></name><name><surname>Buchfuhrer</surname><given-names>MJ</given-names></name><name><surname>Earley</surname><given-names>CJ</given-names></name><name><surname>Hening</surname><given-names>WA</given-names></name><name><surname>Rye</surname><given-names>DB</given-names></name></person-group><article-title>Medical Advisory Board of the Restless Legs Syndrome Foundation. An algorithm for the management of restless legs syndrome</article-title><source>Mayo Clin Proc</source><year>2004</year><volume>79</volume><fpage>916</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.4065/79.7.916</pub-id><pub-id pub-id-type="pmid">15244390</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bayard</surname><given-names>M</given-names></name><name><surname>Avonda</surname><given-names>T</given-names></name><name><surname>Wadzinski</surname><given-names>J</given-names></name></person-group><article-title>Restless legs syndrome</article-title><source>Am Fam Physician</source><year>2008</year><volume>78</volume><fpage>235</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">18697508</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>H&#x000f6;gl</surname><given-names>B</given-names></name><name><surname>Paulus</surname><given-names>W</given-names></name><name><surname>Clarenbach</surname><given-names>P</given-names></name><name><surname>Trenkwalder</surname><given-names>C</given-names></name></person-group><article-title>Restless legs syndrome: Diagnostic assessment and the advantages and risks of dopaminergic treatment</article-title><source>J Neurol</source><year>2006</year><volume>253</volume><fpage>IV22</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1007/s00415-006-4005-3</pub-id><pub-id pub-id-type="pmid">16944353</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desai</surname><given-names>AV</given-names></name><name><surname>Cherkas</surname><given-names>LF</given-names></name><name><surname>Spector</surname><given-names>TD</given-names></name><name><surname>Williams</surname><given-names>AJ</given-names></name></person-group><article-title>Genetic influences in self-reported symptoms of obstructive sleep apnea and restless legs: a twin study</article-title><source>Twin Res</source><year>2004</year><volume>7</volume><fpage>589</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1375/1369052042663841</pub-id><pub-id pub-id-type="pmid">15607009</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Ondo</surname><given-names>WG</given-names></name><name><surname>Rao</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name></person-group><article-title>Genomewide linkage scans identifies a novel susceptibility locus for restless legs syndrome on chromosome 9p</article-title><source>Am J Hum Genet</source><year>2004</year><volume>74</volume><fpage>876</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1086/420772</pub-id><pub-id pub-id-type="pmid">15077200</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winkelmann</surname><given-names>J</given-names></name><name><surname>Muller-Myhsok</surname><given-names>B</given-names></name><name><surname>Wittchen</surname><given-names>HU</given-names></name><name><surname>Hock</surname><given-names>B</given-names></name><name><surname>Prager</surname><given-names>M</given-names></name><name><surname>Pfister</surname><given-names>H</given-names></name><name><surname>Strohle</surname><given-names>A</given-names></name><name><surname>Eisensehr</surname><given-names>I</given-names></name><name><surname>Dichgans</surname><given-names>M</given-names></name><name><surname>Gasser</surname><given-names>T</given-names></name><name><surname>Trenkwalder</surname><given-names>C</given-names></name></person-group><article-title>Complex segregation analysis of restless legs syndrome provides evidence for an autosomal dominant mode of inheritance in early age at onset families</article-title><source>Ann Neurol</source><year>2002</year><volume>52</volume><fpage>297</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1002/ana.10282</pub-id><pub-id pub-id-type="pmid">12205641</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonati</surname><given-names>MT</given-names></name><name><surname>Ferini-Strambi</surname><given-names>L</given-names></name><name><surname>Aridon</surname><given-names>P</given-names></name><name><surname>Oldani</surname><given-names>A</given-names></name><name><surname>Zucconi</surname><given-names>M</given-names></name><name><surname>Casari</surname><given-names>G</given-names></name></person-group><article-title>Autosomal dominant restless legs syndrome maps on chromosome 14q</article-title><source>Brain</source><year>2003</year><volume>126</volume><fpage>1485</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1093/&#x000a0;brain/awg137</pub-id><pub-id pub-id-type="pmid">12764067</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montagna</surname><given-names>P</given-names></name></person-group><article-title>The treatment of restless legs syndrome</article-title><source>Neurological Science</source><year>2007</year><volume>28</volume><fpage>S61</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1007/s10072-007-0739-7</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zucconi</surname><given-names>M</given-names></name><name><surname>Manconi</surname><given-names>M</given-names></name><name><surname>Ferini Strambi</surname><given-names>L</given-names></name></person-group><article-title>Aetiopathogenesis of restless legs syndrome</article-title><source>Neurological Science</source><year>2007</year><volume>28</volume><fpage>47</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1007/s10072-007-0737-9</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mrowka</surname><given-names>M</given-names></name><name><surname>J&#x000f6;bges</surname><given-names>M</given-names></name><name><surname>Berding</surname><given-names>G</given-names></name><name><surname>Schimke</surname><given-names>N</given-names></name><name><surname>Shing</surname><given-names>M</given-names></name><name><surname>Odin</surname><given-names>P</given-names></name></person-group><article-title>Computerized movement analysis and beta-CIT-SPECT in patients with restless legs syndrome</article-title><source>J Neural Transm </source><year>2005</year><volume>112</volume><fpage>693</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.1007/s00702-004-0217-9</pub-id><pub-id pub-id-type="pmid">15517434</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>RP</given-names></name><name><surname>Picchietti</surname><given-names>D</given-names></name><name><surname>Hening</surname><given-names>WA</given-names></name><name><surname>Trenkwalder</surname><given-names>C</given-names></name><name><surname>Walters</surname><given-names>AS</given-names></name><name><surname>Montplaisi</surname><given-names>J</given-names></name></person-group><article-title>Restless Legs Syndrome Diagnosis and Epidemiology workshop at the National Institutes of Health; International Restless Legs Syndrome Study Group. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health</article-title><source>Sleep Med</source><year>2003</year><volume>4</volume><fpage>101</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1016/S1389-9457(03)00010-8</pub-id><pub-id pub-id-type="pmid">14592341</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walters</surname><given-names>AS</given-names></name><name><surname>LeBrocq</surname><given-names>C</given-names></name><name><surname>Dhar</surname><given-names>A</given-names></name><name><surname>Hening</surname><given-names>W</given-names></name><name><surname>Rosen</surname><given-names>R</given-names></name><name><surname>Allen</surname><given-names>RP</given-names></name><name><surname>Trenkwalder</surname><given-names>C</given-names></name><name><surname>International Restless Legs Syndrome StudyGroup</surname><given-names/></name></person-group><article-title>Validation of the international restless legs syndrome study group rating scale for restless legs syndrome</article-title><source>Sleep Med</source><year>2003</year><volume>4</volume><fpage>121</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/S1389-9457(02)00258-7</pub-id><pub-id pub-id-type="pmid">14592342</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zafar</surname><given-names>KS</given-names></name><name><surname>Siddiqui</surname><given-names>A</given-names></name><name><surname>Sayeed</surname><given-names>I</given-names></name><name><surname>Ahmad</surname><given-names>M</given-names></name><name><surname>Salim</surname><given-names>S</given-names></name><name><surname>Islam</surname><given-names>F</given-names></name></person-group><article-title>Dose dependent protective effect of selenium in rat model of Parkinson disease: neurobehavioral and neurochemical evidences</article-title><source>J Neurochem</source><year>2003</year><volume>84</volume><fpage>438</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1046/j.1471-4159.2003.01531.x</pub-id><pub-id pub-id-type="pmid">12558963</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trenkwalder</surname><given-names>C</given-names></name><name><surname>Hening</surname><given-names>WA</given-names></name><name><surname>Montagna</surname><given-names>P</given-names></name><name><surname>Oertel</surname><given-names>WH</given-names></name><name><surname>Allen</surname><given-names>RP</given-names></name><name><surname>Walters</surname><given-names>AS</given-names></name><name><surname>Costa</surname><given-names>J</given-names></name><name><surname>Stiasny-Kolster</surname><given-names>K</given-names></name><name><surname>Sampaio</surname><given-names>C</given-names></name></person-group><article-title>Treatment of restless legs syndrome: An evidence-based review and implications for clinical practice</article-title><source>Mov Disord</source><year>2008</year><volume>23</volume><fpage>2267</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1002/mds.22254</pub-id><pub-id pub-id-type="pmid">18925578</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohrle</surname><given-names>J</given-names></name><name><surname>Jakob</surname><given-names>F</given-names></name><name><surname>Contempre</surname><given-names>B</given-names></name><name><surname>Dumont</surname><given-names>JE</given-names></name></person-group><article-title>Selenium, the thyroid and the endocrine system</article-title><source>Endocr Rev</source><year>2005</year><volume>26</volume><fpage>944</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1210/er.2001-0034</pub-id><pub-id pub-id-type="pmid">16174820</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hogue</surname><given-names>DE</given-names></name></person-group><article-title>Selenium</article-title><source>J Dairy Sci</source><year>1970</year><volume>53</volume><fpage>1135</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.3168/jds.S0022-0302(70)86356-1</pub-id><pub-id pub-id-type="pmid">4918952</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alizadeh</surname><given-names>M</given-names></name><name><surname>Daneghian</surname><given-names>S</given-names></name><name><surname>Ghaffari</surname><given-names>A</given-names></name><name><surname>Ostadrahimi</surname><given-names>AR</given-names></name><name><surname>Safaeiyan</surname><given-names>AR</given-names></name><name><surname>Estakhri</surname><given-names>R</given-names></name><name><surname>Pourghassem Gargari</surname><given-names>B</given-names></name></person-group><article-title>The effect of hypocaloric diet enriched in legumes with or without Larginine and selenium on anthropometric measures in central obese women</article-title><source>J Res Med Sci</source><year>2010</year><volume>15</volume><fpage>331</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">21526106</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boskabadi</surname><given-names>H</given-names></name><name><surname>Rezagholizade Omran</surname><given-names>F</given-names></name><name><surname>Tara</surname><given-names>F</given-names></name><name><surname>Rayman</surname><given-names>MP</given-names></name><name><surname>Ghayour-Mobarhan</surname><given-names>M</given-names></name><name><surname>Sahebkar</surname><given-names>A</given-names></name><name><surname>Tavallaie</surname><given-names>S</given-names></name><name><surname>Shakeri</surname><given-names>MT</given-names></name><name><surname>Alamdari</surname><given-names>DH</given-names></name><name><surname>Kiani</surname><given-names>M</given-names></name><name><surname>Razavi</surname><given-names>BS</given-names></name><name><surname>Oladi</surname><given-names>M</given-names></name><name><surname>Ferns</surname><given-names>G</given-names></name></person-group><article-title>The Effect of Maternal Selenium Supplementation on Pregnancy Outcome and the Level of Oxidative Stress in Neonates</article-title><source>Iran Red Crescent Med J</source><year>2010</year><volume>12</volume><fpage>254</fpage><lpage>259</lpage></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patrick</surname><given-names>L</given-names></name></person-group><article-title>Selenium biochemistry and cancer: a review of the literature</article-title><source>Altern Med Rev</source><year>2004</year><volume>9</volume><fpage>239</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">15387717</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ge</surname><given-names>K</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name></person-group><article-title>The epidemiology of selenium deficiency in the etiological study of endemic diseases in China</article-title><source>Am J Clin Nutr</source><year>1993</year><volume>57</volume><fpage>259S-263S</fpage><pub-id pub-id-type="pmid">8427200</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diplock</surname><given-names>AT</given-names></name></person-group><article-title>Indexes of selenium in human populations</article-title><source>Am J Clin Nutr</source><year>1993</year><volume>57</volume><fpage>256S</fpage><lpage>258S</lpage><pub-id pub-id-type="pmid">8427199</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>HA</given-names></name></person-group><article-title>Selenium partially reverses the depletion of striatal dopamine and its metabolites in MPTP-treated C57BL mice</article-title><source>Neurochem Int</source><year>2010</year><volume>57</volume><fpage>489</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.neuint.2010.06.020</pub-id><pub-id pub-id-type="pmid">20619308</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Talas</surname><given-names>ZS</given-names></name><name><surname>Ozdemir</surname><given-names>I</given-names></name><name><surname>Gok</surname><given-names>Y</given-names></name><name><surname>Ates</surname><given-names>B</given-names></name><name><surname>Yilmaz</surname><given-names>I</given-names></name></person-group><article-title>Role of selenium compounds on tyrosine hydroxylase activity, adrenomedullin and total RNA levels in hearts of rats</article-title><source>Regul Pept</source><year>2010</year><volume>159</volume><fpage>137</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.regpep.2009.08.009</pub-id><pub-id pub-id-type="pmid">19706312</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casta&#x000f1;o</surname><given-names>A</given-names></name><name><surname>Ayala</surname><given-names>A</given-names></name><name><surname>Rodriguez-Gomez</surname><given-names>JA</given-names></name><name><surname>de la Cruz</surname><given-names>CP</given-names></name><name><surname>Revilla</surname><given-names>E</given-names></name><name><surname>Cano</surname><given-names>J</given-names></name><name><surname>Machado</surname><given-names>A</given-names></name></person-group><article-title>Increase in dopamine turnover and tyrosine hydroxylase enzyme in hippocampus of rats fed on low selenium diet</article-title><source>J Neurosci Res </source><year>1995</year><volume>42</volume><fpage>684</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1002/jnr.490420511</pub-id><pub-id pub-id-type="pmid">8600301</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tara</surname><given-names>F</given-names></name><name><surname>Rayman</surname><given-names>MP</given-names></name><name><surname>Boskabadi</surname><given-names>H</given-names></name><name><surname>Ghayour-Mobarhan</surname><given-names>M</given-names></name><name><surname>Sahebkar</surname><given-names>A</given-names></name><name><surname>Alamdari</surname><given-names>DH</given-names></name><name><surname>Razavi</surname><given-names>BS</given-names></name><name><surname>Tavallaie</surname><given-names>S</given-names></name><name><surname>Azimi-Nezhad</surname><given-names>M</given-names></name><name><surname>Shakeri</surname><given-names>MT</given-names></name><name><surname>Oladi</surname><given-names>M</given-names></name><name><surname>Yazarlu</surname><given-names>O</given-names></name><name><surname>Ouladan</surname><given-names>S</given-names></name><name><surname>Sangani</surname><given-names>MT</given-names></name><name><surname>Omran</surname><given-names>FR</given-names></name><name><surname>Ferns</surname><given-names>G</given-names></name></person-group><article-title>Pro oxidant-antioxidant balance in pregnancy: a randomized doubleblind placebo-controlled trial of selenium supplementation</article-title><source>J Perinat Med</source><year>2010</year><volume>38</volume><fpage>473</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1515/JPM.2010.068</pub-id><pub-id pub-id-type="pmid">20629489</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lippman</surname><given-names>SM</given-names></name><name><surname>Klein</surname><given-names>EA</given-names></name><name><surname>Goodman</surname><given-names>PJ</given-names></name><name><surname>Lucia</surname><given-names>MS</given-names></name><name><surname>Thompson</surname><given-names>IM</given-names></name><name><surname>Ford</surname><given-names>LG</given-names></name><name><surname>Parnes</surname><given-names>HL</given-names></name><name><surname>Minasian</surname><given-names>LM</given-names></name><name><surname>Gaziano</surname><given-names>JM</given-names></name><name><surname>Hartline</surname><given-names>JA</given-names></name><name><surname>Parsons</surname><given-names>JK</given-names></name><name><surname>Bearden</surname><given-names>JD 3rd</given-names></name><name><surname>Crawford</surname><given-names>ED</given-names></name><name><surname>Goodman</surname><given-names>GE</given-names></name><name><surname>Claudio</surname><given-names>J</given-names></name><name><surname>Winquist</surname><given-names>E</given-names></name><name><surname>Cook</surname><given-names>ED</given-names></name><name><surname>Karp</surname><given-names>DD</given-names></name><name><surname>Walther</surname><given-names>P</given-names></name><name><surname>Lieber</surname><given-names>MM</given-names></name><name><surname>Kristal</surname><given-names>AR</given-names></name><name><surname>Darke</surname><given-names>AK</given-names></name><name><surname>Arnold</surname><given-names>KB</given-names></name><name><surname>Ganz</surname><given-names>PA</given-names></name><name><surname>Santella</surname><given-names>RM</given-names></name><name><surname>Albanes</surname><given-names>D</given-names></name><name><surname>Taylor</surname><given-names>PR</given-names></name><name><surname>Probstfield</surname><given-names>JL</given-names></name><name><surname>Jagpal</surname><given-names>TJ</given-names></name><name><surname>Crowley</surname><given-names>JJ</given-names></name><name><surname>Meyskens</surname><given-names>FL Jr</given-names></name><name><surname>Baker</surname><given-names>LH</given-names></name><name><surname>Coltman</surname><given-names>CA Jr</given-names></name></person-group><article-title>Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).</article-title><source>JAMA </source><year>2009</year><volume>301</volume><fpage>39</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1001/jama.2008.864</pub-id><pub-id pub-id-type="pmid">19066370</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname><given-names>P</given-names></name><name><surname>Griffith</surname><given-names>A</given-names></name><name><surname>Costantino</surname><given-names>HR</given-names></name><name><surname>Vaish</surname><given-names>N</given-names></name></person-group><article-title>Gabapentin enacarbil - clinical efficacy in restless legs syndrome</article-title><source>Neuropsychiatr Dis Treat</source><year>2010</year><volume>6</volume><fpage>151</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.2147/NDT.S5712</pub-id><pub-id pub-id-type="pmid">20505847</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>H&#x000f6;gl</surname><given-names>B</given-names></name><name><surname>Oertel</surname><given-names>WH</given-names></name><name><surname>Stiasny-Kolster</surname><given-names>K</given-names></name><name><surname>Geisler</surname><given-names>P</given-names></name><name><surname>Bene&#x00161;</surname><given-names>H</given-names></name><name><surname>Garc&#x000ed;a-Borreguero</surname><given-names>D</given-names></name><name><surname>Trenkwalder</surname><given-names>C</given-names></name><name><surname>Poewe</surname><given-names>W</given-names></name><name><surname>Schollmayer</surname><given-names>E</given-names></name><name><surname>Kohnen</surname><given-names>R</given-names></name></person-group><article-title>Treatment of moderate to severe restless legs syndrome: 2-year safety and efficacy of rotigotine transdermal patch</article-title><source>BMC Neurol</source><year>2010</year><volume>10</volume><fpage>86</fpage><pub-id pub-id-type="doi">10.1186/1471-2377-10-86</pub-id><pub-id pub-id-type="pmid">20920156</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walters</surname><given-names>AS</given-names></name><name><surname>Ondo</surname><given-names>WG</given-names></name><name><surname>Dreykluft</surname><given-names>T</given-names></name><name><surname>Grunstein</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>D</given-names></name><name><surname>Sethi</surname><given-names>K</given-names></name></person-group><article-title>TREAT RLS 2 (Therapy with Ropinirole: Efficacy And Tolerability in RLS 2) Study Group. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12- week, double-blind, randomized, parallel-group, placebo-controlled study</article-title><source>Mov Disord</source><year>2004</year><volume>19</volume><fpage>1414</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1002/mds.20257</pub-id><pub-id pub-id-type="pmid">15390050</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aizawa</surname><given-names>H</given-names></name><name><surname>Aburakawa</surname><given-names>Y</given-names></name><name><surname>Suzuki</surname><given-names>Y</given-names></name><name><surname>Enomoto</surname><given-names>H</given-names></name><name><surname>Makita</surname><given-names>Y</given-names></name><name><surname>Kikuchi</surname><given-names>K</given-names></name><name><surname>Kimura</surname><given-names>T</given-names></name><name><surname>Yahara</surname><given-names>O</given-names></name></person-group><article-title>Treatment of Japanese restless legs syndrome patients with cabergoline</article-title><source>Intern Med</source><year>2006</year><volume>45</volume><fpage>453</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.2169/internalmedicine.45.1555</pub-id><pub-id pub-id-type="pmid">16679700</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fulda</surname><given-names>S</given-names></name><name><surname>Wetter</surname><given-names>TC</given-names></name></person-group><article-title>Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studies</article-title><source>Brain</source><year>2008</year><volume>131</volume><fpage>902</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1093/brain/awm244</pub-id><pub-id pub-id-type="pmid">17932100</pub-id></element-citation></ref></ref-list></back></article>